Compare ECPG & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ECPG | GENB |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1999 | 2026 |
| Metric | ECPG | GENB |
|---|---|---|
| Price | $103.47 | $15.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $77.33 | $23.20 |
| AVG Volume (30 Days) | 352.5K | ★ 491.6K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 287.14 | N/A |
| EPS | ★ 6.66 | N/A |
| Revenue | ★ $1,768,802,000.00 | N/A |
| Revenue This Year | $4.53 | N/A |
| Revenue Next Year | $4.76 | $16.58 |
| P/E Ratio | $15.57 | ★ N/A |
| Revenue Growth | ★ 34.37 | N/A |
| 52 Week Low | $39.95 | $11.00 |
| 52 Week High | $104.98 | $18.18 |
| Indicator | ECPG | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 64.86 | 55.37 |
| Support Level | $77.69 | $11.82 |
| Resistance Level | N/A | $16.75 |
| Average True Range (ATR) | 4.07 | 0.80 |
| MACD | 0.70 | 0.18 |
| Stochastic Oscillator | 88.70 | 77.59 |
Encore Capital Group Inc is an international specialty finance company engaged in providing debt recovery solutions and other related services for consumers across a broad range of financial assets. It mainly purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals to repay their obligations and work toward financial recovery. The company also provides debt servicing and other portfolio management services to credit originators for non-performing loans in Europe. It has only one reportable segment, debt purchasing and recovery. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Europe, and other regions.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.